Recent SMMT News
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 07/03/2024 08:15:00 PM
- Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors • Business Wire • 06/27/2024 08:15:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 06/18/2024 09:14:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 09:25:01 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/13/2024 06:03:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 10:18:31 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 10:05:37 AM
- Summit Raises $200 Million; Also Expands License Territories for Ivonescimab • Business Wire • 06/03/2024 09:30:00 AM
- Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA • Business Wire • 06/01/2024 12:00:00 PM
- Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy • Business Wire • 05/31/2024 11:00:00 PM
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/30/2024 10:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:48:30 PM
- Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China • Business Wire • 05/30/2024 06:29:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 12:35:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 12:03:57 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/13/2024 11:48:42 AM
- Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 • Business Wire • 05/01/2024 11:00:00 AM
- Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 • Business Wire • 04/24/2024 08:30:00 PM
- Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors • Business Wire • 04/11/2024 08:30:00 PM
- Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum • Business Wire • 04/10/2024 11:00:00 AM
- Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024 • Business Wire • 03/22/2024 11:00:00 AM
- Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024 • Business Wire • 03/14/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 09:05:09 PM
- Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference • Business Wire • 03/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 01:05:51 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM